Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-04-02 DOI:10.1016/j.pnpbp.2025.111360

Jae-Min Kim , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Min-Gon Kim , Il-Seon Shin

{"title":"Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy","authors":"Jae-Min Kim , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Min-Gon Kim , Il-Seon Shin","doi":"10.1016/j.pnpbp.2025.111360","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Effective predictive biomarkers for depression relapse remain elusive. This study examined the association of a multi-modal serum biomarker panel with relapse among outpatients with depressive disorders under psychopharmacotherapy, utilizing a naturalistic 24-month prospective design.</div></div><div><h3>Methods</h3><div>atients were recruited from a University hospital in South Korea between March 2012 and April 2017. At baseline, 14 serum biomarkers along with socio-demographic and clinical characteristics were assessed in 1094 patients. Following initial antidepressant monotherapy, patients who responded (Hamilton Depression Rating Scale [HAMD] ≤ 14) at the 12-week mark (<em>N</em> = 823) were monitored for relapse (HAMD >14) every three months up to 24 months (<em>N</em> = 710). Logistic regression models, adjusted for relevant covariates, were used to evaluate predictive biomarkers of relapse.</div></div><div><h3>Results</h3><div>The combined scores of four serum biomarkers (cortisol, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and brain-derived neurotrophic factor) showed a significant and graded association with depression relapse (<em>P</em>-value <0.001), even after adjustments.</div></div><div><h3>Conclusions</h3><div>The application of a combined multi-serum biomarker panel could significantly enhance the predictability of depression relapse. Further validation of these biomarkers in diverse populations and settings is warranted to confirm their utility in clinical practice.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"138 ","pages":"Article 111360"},"PeriodicalIF":5.3000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625001149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Effective predictive biomarkers for depression relapse remain elusive. This study examined the association of a multi-modal serum biomarker panel with relapse among outpatients with depressive disorders under psychopharmacotherapy, utilizing a naturalistic 24-month prospective design.

Methods

atients were recruited from a University hospital in South Korea between March 2012 and April 2017. At baseline, 14 serum biomarkers along with socio-demographic and clinical characteristics were assessed in 1094 patients. Following initial antidepressant monotherapy, patients who responded (Hamilton Depression Rating Scale [HAMD] ≤ 14) at the 12-week mark (N = 823) were monitored for relapse (HAMD >14) every three months up to 24 months (N = 710). Logistic regression models, adjusted for relevant covariates, were used to evaluate predictive biomarkers of relapse.

Results

The combined scores of four serum biomarkers (cortisol, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and brain-derived neurotrophic factor) showed a significant and graded association with depression relapse (P-value <0.001), even after adjustments.

Conclusions

The application of a combined multi-serum biomarker panel could significantly enhance the predictability of depression relapse. Further validation of these biomarkers in diverse populations and settings is warranted to confirm their utility in clinical practice.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.